CFL1 (Ab-3) Antibody

What is CFL1 and why is it an important research target?

Cofilin 1 (CFL1) is a critical actin-binding protein with a molecular weight of 18.5 kDa and 166 amino acid residues in humans . It serves as a key regulator of actin cytoskeleton dynamics through its ability to control reversibly actin polymerization and depolymerization in a pH-sensitive manner . The protein binds to both G-actin and F-actin in a 1:1 ratio, functioning as a major component of intranuclear and cytoplasmic actin rods . CFL1 has gained significant research interest due to its involvement in cellular processes like migration, division, and morphological changes, making it relevant to studies in cancer, neurodegeneration, and cardiovascular research. The protein is also known by several synonyms including 18 kDa phosphoprotein, non-muscle cofilin, epididymis secretory protein Li 15, HEL-S-15, and p18 .

What experimental applications is the CFL1 (Ab-3) Antibody validated for?

The CFL1 (Ab-3) Antibody has been validated for multiple experimental applications, specifically Western Blot (WB), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunohistochemistry (IHC) . Western blotting represents one of the most common applications for this antibody, as demonstrated by analysis of extracts from MDA cells . Researchers should note that while these are the validated applications, optimization may be required for specific experimental conditions, cell lines, or tissue types. When designing experiments using this antibody, it is advisable to include appropriate positive controls such as human cell lines known to express CFL1, and negative controls where CFL1 expression is absent or knocked down.

What is the species reactivity profile of CFL1 (Ab-3) Antibody?

The CFL1 (Ab-3) Antibody demonstrates confirmed reactivity to human CFL1 protein . According to the product information, it has been specifically tested and validated for human samples . While CFL1 gene orthologs have been reported in mouse, rat, bovine, frog, and chimpanzee species , researchers working with non-human samples should conduct preliminary validation tests before proceeding with full experiments. The high conservation of CFL1 across species suggests potential cross-reactivity, but experimental verification is necessary for each specific application and species combination.

How should sample preparation be optimized for CFL1 detection using the Ab-3 antibody?

Sample preparation for CFL1 detection requires careful consideration of protein preservation and epitope accessibility. For Western blot applications, samples should be prepared in a buffer containing protease inhibitors to prevent degradation of CFL1 protein. Phosphatase inhibitors are also crucial if studying phosphorylated forms of CFL1, particularly at the Ser3 position which regulates its activity. Cell lysis should be performed using methods that effectively solubilize membrane and cytoskeletal components, as CFL1 interacts closely with actin filaments .

For immunohistochemistry applications, fixation method significantly impacts detection efficiency. Paraformaldehyde fixation (4%) typically preserves CFL1 epitopes while maintaining tissue morphology. Antigen retrieval methods may be necessary, with heat-induced epitope retrieval in citrate buffer (pH 6.0) often proving effective for CFL1 detection. Researchers should optimize blocking conditions (typically 5% BSA or normal serum) to minimize background while maintaining specific signal intensity.

What are the recommended protocols for using CFL1 (Ab-3) Antibody in Western blotting?

When using CFL1 (Ab-3) Antibody for Western blotting, researchers should follow these methodological guidelines:

• Sample preparation: Lyse cells in RIPA buffer containing protease and phosphatase inhibitors.

• Protein separation: Load 20-30 μg of total protein per lane on a 12-15% SDS-PAGE gel (optimal for resolving the 18.5 kDa CFL1 protein).

• Transfer: Use a PVDF membrane with 0.2 μm pore size for efficient transfer of low molecular weight proteins.

• Blocking: Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute CFL1 (Ab-3) Antibody per manufacturer recommendations (typically 1:1000) in blocking buffer and incubate overnight at 4°C.

• Washing: Wash membranes 3-4 times with TBST, 5 minutes each.

• Secondary antibody: Use anti-rabbit HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature.

• Detection: Develop using enhanced chemiluminescence reagents.

This protocol has been verified for detecting CFL1 in MDA cells and can be adapted for other cell types with appropriate optimization.

How can researchers distinguish between total and phosphorylated forms of CFL1?

Distinguishing between total and phosphorylated CFL1 requires specific antibody selection and experimental design. While the CFL1 (Ab-3) Antibody detects total CFL1 regardless of phosphorylation status , specific phospho-CFL1 antibodies targeting the Ser3 site are available from manufacturers like St John's Laboratory (STJ22068) . Researchers investigating CFL1 regulation should implement the following approaches:

• Parallel Western blots: Run duplicate samples on separate blots and probe one with total CFL1 antibody and the other with phospho-specific antibody.

• Sequential immunodetection: Strip and reprobe membranes, though this may reduce sensitivity.

• Dual-color fluorescent detection: Use differentially labeled secondary antibodies (e.g., 680nm and 800nm) to detect both forms simultaneously on the same blot.

• Phosphatase treatment controls: Include samples treated with lambda phosphatase to confirm phospho-antibody specificity.

The ratio of phosphorylated to total CFL1 provides valuable information about actin dynamics regulation in different experimental conditions, as phosphorylation at Ser3 inhibits CFL1's actin-binding and depolymerizing activities.

How can CFL1 (Ab-3) Antibody be utilized in studying cellular migration mechanisms?

CFL1 (Ab-3) Antibody can be instrumental in studying cellular migration through multiple methodological approaches:

• Immunolocalization studies: Use the antibody in immunofluorescence assays to visualize CFL1 distribution at the leading edge of migrating cells, where actin remodeling is most active. Co-staining with phalloidin allows correlation between CFL1 localization and F-actin structures.

• Biochemical fractionation: Employ subcellular fractionation followed by Western blotting with CFL1 (Ab-3) Antibody to quantify CFL1 redistribution between cytosolic and membrane/cytoskeletal fractions during migration.

• Temporal dynamics: Analyze CFL1 phosphorylation status at different time points during migration using phospho-specific antibodies in conjunction with CFL1 (Ab-3) Antibody to determine activation patterns.

• Stimulus-response experiments: Study how chemotactic factors affect CFL1 expression and phosphorylation, referencing previous work that demonstrated "time-course effect of a chemokine on phosphorylation of cofilin in Human" cells .

• Proximity ligation assays: Combine CFL1 (Ab-3) Antibody with antibodies against migration-related proteins to detect protein-protein interactions during cellular movement.

These approaches provide mechanistic insights into how CFL1-mediated actin remodeling contributes to cellular migration in both physiological and pathological contexts.

What methodological approaches can resolve contradicting data when studying CFL1 across different experimental platforms?

When researchers encounter contradicting data using CFL1 (Ab-3) Antibody across different experimental platforms, several methodological strategies can help resolve these discrepancies:

• Epitope accessibility assessment: Different fixation, permeabilization, or antigen retrieval methods may affect epitope exposure. Systematically compare protocols to identify optimal conditions for each platform.

• Antibody validation panel: Use multiple antibodies targeting different epitopes of CFL1 to confirm findings. The use of knockout/knockdown controls is essential to verify antibody specificity.

• Orthogonal technique confirmation: Verify protein expression findings with mRNA analysis (RT-qPCR) or mass spectrometry-based proteomics.

• Phosphorylation status consideration: Contradictory results may stem from differences in CFL1 phosphorylation. Analyze both total and phosphorylated forms using specific antibodies.

• Sample preparation standardization: Develop consistent sample preparation protocols across platforms, particularly regarding phosphatase and protease inhibitor usage.

• Quantification method normalization: Standardize quantification methods and use appropriate housekeeping controls for each experimental platform.

These approaches have successfully resolved contradictions in studies examining CFL1 expression in different tissues from diabetic and non-diabetic models .

How can researchers investigate the relationship between CFL1 and disease pathogenesis?

Investigating the relationship between CFL1 and disease pathogenesis requires multi-faceted experimental approaches utilizing CFL1 (Ab-3) Antibody:

• Expression profiling: Compare CFL1 expression levels between healthy and diseased tissues using Western blot and immunohistochemistry. This approach has been successfully used in brain microvascular endothelial studies and could be extended to other tissues.

• Phosphorylation status analysis: Assess CFL1 activity regulation by examining Ser3 phosphorylation patterns in disease models, as aberrant phosphorylation may contribute to pathological actin dynamics.

• Colocalization studies: Perform dual immunofluorescence staining with CFL1 (Ab-3) Antibody and disease-specific markers to establish spatial relationships in affected tissues.

• Intervention studies: Monitor CFL1 expression and phosphorylation changes following therapeutic interventions to establish causative relationships.

• Genetic model correlation: Compare CFL1 expression patterns with genetic variations or mutations associated with specific diseases using immunoblotting techniques.

This methodological framework has been particularly valuable in investigating CFL1's role in neurodegenerative disorders, where abnormal actin dynamics contribute to synaptic dysfunction, and in diabetic complications affecting liver and kidney tissues .

What are common issues when using CFL1 (Ab-3) Antibody and how can they be resolved?

Researchers may encounter several challenges when working with CFL1 (Ab-3) Antibody. Here are methodological solutions to common technical issues:

• Weak or absent signal in Western blot:

  • Increase antibody concentration or incubation time

  • Optimize protein loading (20-30 μg recommended)

  • Use enhanced sensitivity detection systems

  • Check transfer efficiency for low molecular weight proteins

  • Verify sample preparation to ensure protein integrity

• High background in immunostaining:

  • Increase blocking duration and concentration (5-10% BSA)

  • Optimize antibody dilution (typically start with 1:200 for IHC)

  • Include detergent (0.1-0.3% Triton X-100) in washing steps

  • Consider autofluorescence reducing agents for fluorescent applications

• Non-specific bands in Western blot:

  • Increase washing stringency using higher salt concentration

  • Use gradient gels to better resolve the 18.5 kDa CFL1 band

  • Include competitive blocking with peptides

• Variable results between experiments:

  • Standardize lysate preparation procedures

  • Prepare single-use aliquots of antibody to avoid freeze-thaw cycles

  • Include consistent positive controls in each experiment

• Phosphorylation-dependent detection issues:

  • Ensure phosphatase inhibitors are fresh and used at appropriate concentrations

  • Process samples rapidly at cold temperatures to preserve phosphorylation status

Implementing these methodological refinements can significantly improve reliability when working with CFL1 (Ab-3) Antibody across different experimental platforms.

How can researchers validate the specificity of CFL1 (Ab-3) Antibody in their experimental system?

Validating the specificity of CFL1 (Ab-3) Antibody is crucial for reliable research outcomes. Researchers should implement the following methodological approach:

• Genetic knockdown/knockout controls:

  • Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate CFL1 expression

  • Confirm diminished or absent signal with the antibody in Western blot or immunostaining

• Peptide competition assay:

  • Pre-incubate the antibody with excess cognate peptide before application

  • Specific signals should be significantly reduced or eliminated

• Multiple antibody comparison:

  • Test multiple antibodies targeting different epitopes of CFL1

  • Consistent patterns across antibodies support specificity

• Orthogonal method validation:

  • Correlate protein detection with mRNA levels using RT-qPCR

  • Consider mass spectrometry-based validation for absolute confirmation

• Species cross-reactivity assessment:

  • Test the antibody against samples from multiple species if working with non-human models

  • Compare observed molecular weights with predicted values for each species

• Isotype control experiments:

  • Use non-specific IgG from the same species (rabbit) at the same concentration

  • Helps distinguish specific binding from Fc receptor interactions

These validation steps establish a solid foundation for interpreting experimental results and are particularly important when studying CFL1 in novel systems or conditions.

How can CFL1 (Ab-3) Antibody be utilized in multiplex immunoassays?

Incorporating CFL1 (Ab-3) Antibody into multiplex immunoassays requires methodological considerations to ensure compatibility and reliable detection alongside other targets:

• Panel design considerations:

  • Select complementary antibodies raised in different host species to avoid secondary antibody cross-reactivity

  • When using rabbit-derived CFL1 (Ab-3) Antibody, pair with mouse, goat, or chicken-derived antibodies for other targets

  • Consider size separation of targets to avoid signal overlap (CFL1 at 18.5 kDa)

• Fluorescent multiplexing optimization:

  • Select fluorophores with minimal spectral overlap for conjugated secondary antibodies

  • Account for relative abundance differences between CFL1 and other targets

  • Optimize signal amplification methods for less abundant proteins

• Sequential detection protocols:

  • For chromogenic multiplex IHC, use sequential detection with thorough blocking between rounds

  • Consider tyramide signal amplification for enhanced sensitivity

• Validation strategies:

  • Run single-plex controls alongside multiplex assays to confirm signal specificity

  • Include appropriate blocking controls to prevent non-specific binding

• Data analysis approaches:

  • Implement spectral unmixing algorithms to separate overlapping signals

  • Use colocalization analysis to study spatial relationships between CFL1 and other proteins

This methodological framework enables researchers to investigate CFL1 in the context of other proteins involved in actin dynamics, signal transduction, or disease pathways.

What emerging research areas benefit from CFL1 (Ab-3) Antibody applications?

CFL1 (Ab-3) Antibody is finding new applications in several cutting-edge research areas:

• Neurodegenerative disease mechanisms:

  • Studying CFL1-mediated actin dynamics in dendritic spine pathology

  • Investigating aggregation of cofilin-actin rods in Alzheimer's disease models

  • Exploring synaptic plasticity dysfunction in relation to CFL1 activity

• Cancer metastasis and invasion:

  • Analyzing CFL1 phosphorylation status in invasive cancer cells

  • Correlating CFL1 expression with metastatic potential

  • Investigating CFL1 as a biomarker for cancer progression

• Immune cell function:

  • Studying the role of CFL1 in immunological synapse formation

  • Analyzing T-cell activation in relation to CFL1-mediated actin remodeling

  • Investigating neutrophil migration and phagocytosis mechanisms

• Response to therapeutic interventions:

  • Monitoring CFL1 activity as a marker for cytoskeletal drug efficacy

  • Assessing actin dynamics modulation in response to experimental therapeutics

  • Using CFL1 phosphorylation status as a pharmacodynamic marker

• Interactions with viral pathogens:

  • Investigating CFL1's role in viral entry and replication

  • Studying host cytoskeletal responses to infection, particularly relevant to recent research on SARS-CoV-2

  • Analyzing viral manipulation of actin dynamics through CFL1 modulation

These emerging areas highlight the versatility of CFL1 (Ab-3) Antibody as a tool for understanding fundamental biological processes and disease mechanisms.